CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Announces Progress in Commercialization Plan with Initial Product Expected in Q1 2021

December 16, 2020 11:41:49

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) has contracted with a leading manufacturer to produce its first cannabinoid, cannabigerol (“CBG”); the first production run is slated for early 2021 and will result in commercial quantities of Willow’s ultra-pure CBG. The product will be manufactured in Europe. In addition, Willow announced plans to run a second 500-litre pilot this month in order to meet demand for customer samples and streamline the production process. These announcements mark significant progress for the company in its strategic commercialization plan. Based on progress so far, the company noted that it anticipates seeing revenue generated from this commercialization as early as Q2 2021, which is six months ahead of expectations. “Advancing to commercial-scale production is the final step in our transition to becoming a revenue generating company,” said Willow president and CEO Trevor Peters in the press release. “Our ability to begin this important milestone ahead of expectations is a testament to our exceptional scientific and commercially minded team. We are seeing strong interest in our CBG samples and are working closely to understand the needs of potential customers. Once our commercial scale multi-kilogram run is complete, Willow will be uniquely positioned to take advantage of what many industry experts are projecting to be a multi-billion dollar market.”

To view the full press release, visit

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Vancouver, British Columbia , that produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

CannabisNewsWire is part of the InvestorBrandNetwork.